Autoimmunity Link in Long COVID Patients
Researchers identified autoantibodies as a driver of long COVID symptoms in a subset of individuals, suggesting new treatment pathways.
Researchers identified autoantibodies as a driver of long COVID symptoms in a subset of individuals, suggesting new treatment pathways.
Researchers identified autoantibodies as a driver of long COVID symptoms in a subset of individuals, suggesting new treatment pathways.
Read MoreNew research suggests that microplastic particles can bind to allergens and carry them deeper into the respiratory system.
Read MorePhase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read MoreA study found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications.
Read MoreResearchers assessed salt intake in cystic fibrosis patients undergoing treatment with CFTR modulators, which improve salt conservation and other physiological markers.
Read MorePapzimeos (zopapogene imadenovec) is recommended as the new first-line treatment for adults with recurrent respiratory papillomatosis (RRP), which affects an estimated 27,000 US adults.
Read MoreA 30 mg peanut oral immunotherapy maintenance dose improved peanut tolerance to a similar extent as a higher 300 mg dose, while being associated with fewer systemic adverse events.
Read MoreCircadian rhythms of the host are a critical determinant of outcomes and may be modified by well-timed environmental cues with potential to drive outcomes in severe flu infection.
Read MoreEczema is more than just a coexisting condition—it may directly influence whether children overcome food allergies.
Read MoreOral immunotherapy and oral food challenges (OFCs) are both safe for young patients and can be life-changing for families navigating food allergies.
Read MoreResearchers used machine learning to identify a unique new subtype of COPD: the emphysema inflammatory subgroup (EIS), which differs from other COPD subtypes in its immune profile and a more distinctive form of emphysema.
Read MoreAn eight-week exercise-based rehabilitation program improved immune function in patients with long COVID.
Read MoreTumors rewire immune cells in the bone marrow before they even reach the cancer, suggesting a new target to enhance the durability of current immunotherapy.
Read MoreAdding immunotherapy (nivolumab) to chemotherapy before surgery significantly improved long-term overall survival for patients with operable non-small cell lung cancer (NSCLC) compared to chemotherapy alone.
Read MoreInfants hospitalized with severe COVID-19 have significantly different immune responses than adults or older children, according to research published in Nature Communications.
Read MoreSARS-CoV-2, the virus that causes COVID-19, can “reprogram” pathogen-fighting white blood cells known as neutrophils into immune system suppressing cells known as PMN-MDSCs.
Read MoreMicroplastics suppress pulmonary macrophages, a type of white blood cell found in the lungs that are critical to the immune system.
Read MoreNetworks of misplaced immune cells drive idiopathic pulmonary fibrosis — a discovery that may create a pathway to new treatments.
Read MoreTwo potential asthma treatments that target key molecules to prevent immune cells from triggering asthma attacks, offering the possibility of long-term relief.
Read MoreRecommendations from ACAAI, AAAAI, and AAOA aim to simplify documentation requirements for allergen immunotherapy claims to prevent undue burden on healthcare providers and ensure timely patient access.
Read MoreThe approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read MoreThe $12 million NIH grant will fund research on how lung neutrophils contribute to injury, inflammation, and repair in severe respiratory conditions.
Read MoreThe Food Allergy Institute’s study shows that 100% of participants achieved milk allergy remission, with results maintained for at least a year.
Read MoreThe novel approach has yielded a 67% overall response rate in a small clinical trial for patients with advanced non-small cell lung cancer.
Read More